Literature DB >> 19799126

[The prognostic value of a modified WPSS based on routine laboratory parameters in patients with myelodysplastic syndromes: a preliminary result].

Lin Li1, Ling Nie, Ming-hua Yu, Yang Yu, Liang Liu, Tie-jun Qin, Ze-feng Xu, Yue Zhang, Zhi-jian Xiao.   

Abstract

OBJECTIVE: To investigate the prognostic value of a modified WPSS based on routine laboratory parameters in Chinese patients with myelodysplastic syndromes (MDS).
METHODS: One hundred and sixty four adult MDS patients were retrospectively analyzed.
RESULTS: The median follow-up time was 19 (1-138) months and the median survival (MS) was 36 months. 2-year prospective survival (PS) was 60% and 5-year PS was 42%. In patients with very low-risk, low-risk, intermediate-risk, high-risk and very high-risk stratified by WPSS, 2-year PS was 100%, 96%, 81%, 38% and 14%, and 5-year PS was 100%, 83%, 54%, 20% and 0, respectively (P<0.01). Among parameters of laboratory routine examination, elevated mean cell volume (MCV), mean cell hemoglobin (MCH), neutrophil alkaline phosphatase (N-ALP) index and nucleated RBC PAS negative were good prognostic factors, while reduced Hb, BPC and bone marrow elevated blasts, dysplasia more than 1 lineage, and lymphocyte-like micromegakaryocyte (MEGly) as well as elevated serum LDH were poor prognostic factors in uni-variable analysis. Among them, MCV, MEGly and blast had independent prognostic significance in multi-variable analysis (P = 0.011, 0.013 and 0.016, respectively). WPSS was modified by omitting chromosomal karyotype and transfusion dependence and adding MCV and MEGly. In patients with low-risk, intermediate-risk and high-risk stratified by modified WPSS, 2-year PS was 94%, 68% and 49%, respectively; and 5-year PS was 86%, 53% and 14%, respectively (P<0.01).
CONCLUSION: The modified WPSS worked well for prognostic prediction in Chinese patients with MDS.

Entities:  

Mesh:

Year:  2009        PMID: 19799126

Source DB:  PubMed          Journal:  Zhonghua Xue Ye Xue Za Zhi        ISSN: 0253-2727


  2 in total

1.  [Mean corpuscular volume ≤100 fl was an independent prognostic factor in patients with myelodysplastic syndrome and bone marrow blast<5 percent].

Authors:  Z X Shi; T J Qin; Z F Xu; H J Huang; B Li; S Q Qu; N B Hu; L J Pan; D Liu; Y N Cai; Y D Zhang; Z J Xiao
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2020-01-14

2.  A favorable inductive remission rate for decitabine combined with chemotherapy as a first course in <60-year-old acute myeloid leukemia patients with myelodysplasia syndrome features.

Authors:  Fengqi Liu; Hehua Wang; Junru Liu; Zhenhai Zhou; Dong Zheng; Beihui Huang; Chang Su; Waiyi Zou; Duorong Xu; Xiuzhen Tong; Juan Li
Journal:  Cancer Med       Date:  2019-07-19       Impact factor: 4.452

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.